News Image

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.

By Mill Chart

Last update: Jan 10, 2024

Exploring Growth Potential: HALOZYME THERAPEUTICS INC (NASDAQ:HALO) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and HALOZYME THERAPEUTICS INC has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected HALOZYME THERAPEUTICS INC on our screen for growth with base formation, suggesting it merits a closer look.

ChartMill's Evaluation of Growth

ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:HALO, the assigned 8 reflects its growth potential:

  • The Earnings Per Share has grown by an nice 12.96% over the past year.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 42.34% on average per year.
  • HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.42%.
  • Measured over the past years, HALO shows a quite strong growth in Revenue. The Revenue has been growing by 15.83% on average per year.
  • The Earnings Per Share is expected to grow by 25.42% on average over the next years. This is a very strong growth
  • HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.85% yearly.

Looking at the Health

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:HALO scores a 7 out of 10:

  • HALO has an Altman-Z score of 3.30. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • HALO has a better Altman-Z score (3.30) than 71.74% of its industry peers.
  • HALO has a better Debt to FCF ratio (4.24) than 94.92% of its industry peers.
  • A Current Ratio of 7.63 indicates that HALO has no problem at all paying its short term obligations.
  • The Current ratio of HALO (7.63) is better than 68.19% of its industry peers.
  • HALO has a Quick Ratio of 6.51. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • HALO's Quick ratio of 6.51 is fine compared to the rest of the industry. HALO outperforms 62.44% of its industry peers.

How do we evaluate the Profitability for NASDAQ:HALO?

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:HALO, the assigned 8 is a significant indicator of profitability:

  • With an excellent Return On Assets value of 13.41%, HALO belongs to the best of the industry, outperforming 98.65% of the companies in the same industry.
  • The Return On Equity of HALO (101.89%) is better than 99.83% of its industry peers.
  • HALO has a better Return On Invested Capital (14.39%) than 97.80% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for HALO is significantly above the industry average of 13.22%.
  • The last Return On Invested Capital (14.39%) for HALO is well below the 3 year average (36.78%), which needs to be investigated, but indicates that HALO had better years and this may not be a problem.
  • Looking at the Profit Margin, with a value of 32.53%, HALO belongs to the top of the industry, outperforming 98.65% of the companies in the same industry.
  • HALO's Profit Margin has improved in the last couple of years.
  • HALO's Operating Margin of 40.35% is amongst the best of the industry. HALO outperforms 98.98% of its industry peers.
  • HALO's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 76.68%, HALO belongs to the best of the industry, outperforming 85.28% of the companies in the same industry.

Looking at the Setup

ChartMill also assign a Setup Rating to every stock. With this score it is determined to what extend the stock has been trading in a range in the recent days and weeks. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. NASDAQ:HALO scores a 7 out of 10:

HALO has a bad technical rating, but it does show a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. There is very little resistance above the current price. There is a support zone below the current price at 34.63, a Stop Loss order could be placed below this zone.

Our Strong Growth screener lists more Strong Growth stocks and is updated daily.

Our latest full fundamental report of HALO contains the most current fundamental analsysis.

Check the latest full technical report of HALO for a complete technical analysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (4/23/2024, 7:03:25 PM)

After market: 38.94 -0.03 (-0.08%)

38.97

+0.26 (+0.67%)

HALO News

News Image19 hours ago - Halozyme Therapeutics, Inc.Halozyme to Report First Quarter 2024 Financial and Operating Results

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results...

News Image21 hours ago - ChartmillNASDAQ:HALO is not too expensive for the growth it is showing.

NASDAQ:HALO stands out as a growth opportunity that won't break the bank.

News Image8 days ago - ChartmillInvestors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.

News Image11 days ago - Market News VideoNotable Two Hundred Day Moving Average Cross - HALO
News Image19 days ago - ChartmillNASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.

News Image26 days ago - BusinessInsiderThe 3 Best Biotech Stocks to Buy in Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech is an industry full of opportunity. It’s also known as one of the...

News Image26 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in Q2 2024

Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.

News Imagea month ago - Market News VideoFirst Week of May 17th Options Trading For Halozyme Therapeutics (HALO)
News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

News Imagea month ago - InvestorPlace7 Biotech Stocks to Buy as Sector Rotation Ramps Up

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

News Image2 months ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is...

News Image2 months ago - Market News VideoHalozyme Therapeutics Breaks Above 200-Day Moving Average - Bullish for HALO
HALO Links
Follow us for more